“Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Plaque Psoriasis: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials” (2019) SKIN The Journal of Cutaneous Medicine, 3, p. S29. doi:10.25251/skin.3.supp.29.